Methoxy polyethylene glycol-epoetin beta - Roche

Drug Profile

Methoxy polyethylene glycol-epoetin beta - Roche

Alternative Names: C.E.R.A.; CERA; Continuous erythropoietin receptor activator; Epoetin beta pegol; Mircera; R-744; RG744; RO 503821; RO-0503821

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche
  • Class Antianaemics; Colony-stimulating factors; Erythropoietins; Haematopoietic cell growth factors; Polyethylene glycols
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia
  • Discontinued Chemotherapy-induced anaemia

Most Recent Events

  • 19 Mar 2018 Registered for Anaemia in Japan (IV, 12.5μg)
  • 19 Mar 2018 Registered for Anaemia in Japan (SC, 12.5μg)
  • 27 Sep 2017 Vifor Pharma expands license agreement with Roche for commercialisation of Methoxy polyethylene glycol-epoetin beta in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top